Skip to main content
Ginkgo Bioworks logo
DNA.NYSE
Ginkgo Bioworks
Healthcare · Biotechnology

Synthetic biology platform company programming cells for biotechnology, pharmaceuticals, agriculture, and industrial applications.

HQ: United StatesListed: United States

Profile & Fundamentals

Review the profile, reported financial history, AI financial assessment, dividends, splits, and dated events for Ginkgo Bioworks.

Profile & Fundamentals

Ginkgo Bioworks Profile & Fundamentals

Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.

Interactive annual & quarterly chartsAI financial reviewsReported source tables
Explore this pageJump to a Profile & Fundamentals section

Company and Market Context

Company Profile & Ownership

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

DNA.NYSE

Company profile record

Ginkgo Bioworks Holdings

Common Stock · Healthcare · Biotechnology

Official website

Company

Company / asset
Ginkgo Bioworks Holdings
Security type
Common Stock
Sector
Healthcare
Industry
Biotechnology
HQ
🇺🇸 United States
Head office
27 Drydock Avenue, Boston, MA, United States, 02210

Leadership & scale

Chief executive
Dr. Jason Kelly Ph.D.
CEO year born
1981
Full-time employees
485
Fiscal year end
December
IPO date
2021-04-19

Fundamentals snapshot

Updated 2026-07-27
Market Cap
USD 481.9M
P/E
--
Revenue (Q1 26)
USD 19.5M
Profit (Q1 26)
USD -82.6M
Dividend Yield
--
Revenue (FY 25)
USD 170.2M
Shares in public float
47.9M
Insider ownership
4.6%

Reporting & identifiers

Symbol
DNA.NYSE
Listing
🇺🇸 United States | Dividend Tax: 30%
Ticker Currency
USD
Income Statement Currency
USD
Balance Sheet Currency
USD
Cash Flow Currency
USD
EPS Currency
USD
Contract Type
SPOT
ISIN
US37611X2099
Asset ID
equity_d620e41c-a941-50d1-953a-a198ca15eb5f

Ownership

Shares Outstanding

Latest: 59.6M | Max: 59.6M | Min: 29.0M

Shares Outstanding
75.1M56.3M37.5M18.8M0.00
'19
'21
'23
'25
'26

Complete Research Workspace

Unlock the complete Profile & Fundamentals

Sign in to verify your access, or upgrade to the Base plan to open every chart, financial statement, event, and source table.